Scientific Advisory Board Member
Mori is a research professor and senior research fellow of the National Health and Medical Council of Australia in the School of Medicine and Pharmacology, University of Western Australia, Perth. He is interested in various aspects of nutrition, hypertension, atherosclerosis and cardiovascular disease (CVD), with a research focus on omega-3 fatty acids and CVD. Other research interests include the role of lipid oxidation in atherosclerosis and CVD; fatty acid metabolism; anti-inflammatory omega-3 fatty acid-derived resolvins and protectins; platelet and leukocyte function; and control mechanisms in blood pressure regulation.
Mori’s research has been supported by the U.S. National Institutes of Health, National Health and Medical Research Council of Australia, National Heart Foundation of Australia and Australian Research Council. He has more than 160 peer-reviewed papers in leading international medical and scientific journals.
Select publications:
Bao DQ, Mori TA, Burke V, et al. Effects of dietary fish and weight reduction on ambulatory blood pressure in overweight hypertensives. Hypertension 1998;32:710-717.
Mori TA, Bao, Burke V, et al. Dietary fish as a major component of a weight reducing diet: impact on serum lipids, glucose and insulin metabolism in overweight hypertensive subjects. Am J Clin Nutr 1999;70:817-825.
Mori TA, Watts GF, Burke V, et al. Differential effects of eicosapentaenoic acid and docosahexaenoic acid on forearm vascular reactivity of the microcirculation in hyperlipidaemic, overweight men. Circulation 2000;102:1264-1269.
Mori TA, Bao DQ, Burke V, et al. Purified eicosapentaenoic acid and docosahexaenoic acid have differential effects of on serum lipids and lipoproteins, LDL – particle size, glucose and insulin, in mildly hyperlipidaemic men. Am J Clin Nutr 2000;71:1085-1094.
Woodman RJ, Mori TA, Burke V, et al. Effects of purified eicosapentaenoic acid and docosahexaenoic acid on glycaemic control, blood pressure and serum lipids in treated-hypertensive Type 2 diabetic patients. Am J Clin Nutr 2002;76:1007-1015.
Mori TA, Woodman RJ, Burke V, et al. Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers, in treated-hypertensive Type 2 diabetic subjects. Free Rad Biol Med 2003;35:772-781.
Barden A, Dunstan JA, Beilin LJ, et al. n-3 Fatty acid supplementation during pregnancy in women with allergic disease: effects on blood pressure, and maternal and fetal lipids. Clin Science 2006;111:289-294.
Proudfoot JM, Barden AE, Loke WM, et al. High density lipoprotein is the major carrier of plasma F2-isoprostanes. J Lipid Res 2009;50:716-722. Editorial: J Lipid Res 2009;50: 599-601.
Mori TA, Burke V, Puddey IB, et al. The effects of w3 fatty acids & coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial. J Hypertens 2009;27:1863–1872.
Mas E, Woodman RJ, Burke V, et al. The omega-3 fatty acids EPA and DHA decrease plasma F2-isoprostanes: results from two placebo-controlled interventions. Free Rad Res 2010;44:983-990.